𝔖 Bobbio Scriptorium
✦   LIBER   ✦

19 Working on asymmetry in Parkinson’s disease: A double-blind, randomized, controlled rehabilitation trial

✍ Scribed by L. Ricciardi; D. Ricciardi; F. Lena; M. Petracca; S. Barricella; N. Modugno; G. Zuccalà; A.R. Bentivoglio; A. Fasano

Book ID
119192859
Publisher
Elsevier
Year
2012
Tongue
English
Weight
47 KB
Volume
2
Category
Article
ISSN
2210-5336

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

Double-blind, randomized, controlled tri
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
✍ Matthew B. Stern; Kenneth L. Marek; Joseph Friedman; Robert A. Hauser; Peter A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

## Abstract Rasagiline (__N__‐propargyl‐1(__R__)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients n

A randomized, double-blind trial of tran
A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease
✍ Holly A. Shill; Sanja Obradov; Yakov Katsnelson; Ray Pizinger 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty‐three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unif

Entacapone to tolcapone switch: Multicen
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease
✍ The Entacapone to Tolcapone Switch Study Investigators 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract This double‐blind study examined the efficacy and safety of replacing entacapone with tolcapone in fluctuating Parkinson's disease (PD) patients. Patients receiving entacapone for ≥15 days were randomly assigned to continue entacapone (n = 75) or switch to tolcapone (n = 75) and were fo

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to